BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  Olink reports first quarter 2024 financial results

  Olink Holding AB announced its unaudited financial results for the first quarter ended March 31, 2024.

  May 13, 2024

   · 

  15 min read
• Business

  Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

  Fulcrum Therapeutics, Inc.® announced that it has entered into a collaboration and license agreement with Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.

  May 13, 2024

   · 

  8 min read
• Pharm Country

  Dramatic Increase in Fentanyl Seized by Authorities in Last Six Years

  The number of illicit fentanyl seizures by law enforcement in the United States grew by more than 1,700 percent between 2017 and 2023, according to a new analysis.

  May 13, 2024

   · 

  4 min read
• Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses

  Pharvaris announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology ; the 2024 Eastern Allergy Conference ; and the European Academy of Allergy and Clinical Immunology Congress 2024.

  May 13, 2024

   · 

  3 min read
• Drug Development

  Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

  Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial.

  May 13, 2024

   · 

  52 min read
• Business

  Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

  Tourmaline Bio, Inc. announced its financial results for the first quarter ended March 31, 2024 and outlined recent business highlights.

  May 13, 2024

   · 

  8 min read
• Business

  Galera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesCompany’s evaluation of potential strategic alternatives progresses with goal to maximize stockholder value

  Galera Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates.

  May 13, 2024

   · 

  7 min read
• BioCapital

  Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock

  Incyte Corporation announced that its Board of Directors approved a share repurchase authorization of $2.0 billion.

  May 13, 2024

   · 

  9 min read
• Genetown

  Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic

  Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms, announced the closing of an oversubscribed $95 million Series C financing.

  May 13, 2024

   · 

  5 min read
• Business

  Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain

  Avanos Medical, Inc. announced that Sigfrido Delgado has been appointed senior vice president, integrated supply chain.

  May 13, 2024

   · 

  1 min read